Menarini Group and Insilico Medicine Enter into Agreement for AI-Discovered Preclinical Oncology Asset
Monday, January 13, 2025
Menarini Group has announced a new licensing agreement with Insilico Medicine.
MEN2312, developed through Insilico’s AI-driven R&D platform, inhibits KAT6 and blocks endocrine receptor (ER) activity at the transcriptional level. This mechanism offers the potential to address resistance to endocrine therapies caused by mutations or ligand-independent activation of ER.
Preclinical studies have shown strong efficacy and safety profiles for MEN2312 across multiple cancer models.
This partnership builds on an earlier agreement established in January 2024, which focused on MEN2312, a novel small molecule designed for breast cancer and other oncology applications.
This marks the second collaboration between the organisations, focusing on the development and commercialisation of a preclinical small molecule targeting high unmet needs in oncology.
The asset, developed using Insilico’s Chemistry42 platform and drug discovery expertise, is described as a highly selective small molecule inhibitor with potential best-in-class properties.
It has successfully completed preclinical development, demonstrating broad anti-tumour activity across various solid cancers.
Under the terms of the agreement, Stemline will pay Insilico $20 million upfront, with the total deal value exceeding $550 million, contingent on development, regulatory, and commercial milestones. Additionally, tiered royalties on sales will be included.
This latest collaboration highlights a shared commitment to advancing innovative therapies in oncology, aiming to address critical gaps in cancer treatment.
Source: menarini.com
